ERBB2 and breast carcinoma: Additionally, molecular analyses were only performed on the initial diagnostic biopsy, and no biopsy was conducted at disease recurrence, which could be a limitation, as HER2 and AR expression can evolve over time, as observed in breast cancer [38, 39].